PBRM1 and chordoma: In a case report, a patient with chordoma receives pembrolizumab and achieves a PFS of 9.3 months by targeting PD-1 receptors of lymphocytes [32], but the immunotherapy benefit may be related to the A1209fs mutation of the PBRM1 gene [32].